Longevity Drugs Enter Clinical Trials: Can Science Slow Aging Itself?
By Sanna the Weaver • Mon Feb 09 2026 • Health
The idea that aging itself is a disease — or at least a biological process that medicine can intervene in — has moved from fringe speculation to mainstream biomedical research in less than a decade. In 2026, for the first time, drugs specifically designed to slow or reverse hallmarks of biological aging are entering human clinical trials that will produce real evidence about whether this approach works. The question is no longer whether the biology supports targeting aging — it does, convincingly — but whether the interventions designed around that biology translate into human benefit. The Biology of Aging Research over the past fifteen years has identified a set of biological processes that drive aging across species — the "hallmarks of aging" first formally catalogued in 2013 and significantly expanded in 2023. These include genomic instability, telomere shortening, epigenetic alterations, loss of proteostasis (the cell's protein-folding quality control system), dysregulation of nutrient-sensing pathways, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and chronic inflammation. Drugs targeting each of these pathways have shown lifespan-extending effects in model organisms including yeast, worms, flies, and mice. The challenge is validating these effects in humans. Senolytics: The Clearest Human Data So Far Senescent cells — cells that have stopped dividing but remain metabolically active, secreting inflammatory molecules — accumulate with age and are now believed to drive many age-related diseases. Senolytic drugs, which selectively kill senescent cells, have shown promising results in small human trials for specific conditions including diabetic kidney disease, idiopathic pulmonary fibrosis, and osteoarthritis. Unity Biotechnology's UBX1325, targeting senescent cells in the eye, has shown positive Phase 2 results in diabetic macular edema. In 2026, a larger trial of the senolytic combination dasatinib plus quercetin is running specifically to assess effects on biological age as measured by epigenetic clocks — the first trial designed not around a specific disease endpoint but around aging biology itself. "Aging is the leading risk factor for virtually every disease that kills people in the developed world. If we can target aging, we target them all simultaneously." — UNITY Biotechnology Chief Scientific Officer, January 2026 Rapamycin and the Longevity Debate Rapamycin, an immunosuppressant approved in 1999 for organ transplant rejection, has become the longevity community's most discussed candidate drug. In mice, it reliably extends both maximum and median lifespan — even when given late in life. Mechanistic studies suggest it works through inhibition of the mTOR pathway, a key nutrient-sensing regulator. The PEARL trial — the first randomized, placebo-controlled trial of low-dose rapamycin in healthy older adults — is reporting interim data in 2026, and the longevity research community is watching with close attention. The drug's known side effects at high doses, including immunosuppression, make it controversial for use in healthy people; the PEARL trial's low-dose protocol is designed to assess whether benefits can be achieved without these risks.